20th of December, 2024 – Uppsala, Sweden,

​PeptiSystems, a biotech company specializing in innovative manufacturing solutions for peptide and oligonucleotide drugs, has successfully raised 45 MSEK in a funding round led by Sciety and Sciety Venture Partners. The investment will support the company’s mission to address growing global demand by expanding production capacity, scaling sales efforts, and advancing sustainable pharmaceutical manufacturing.

While peptide and oligonucleotide drugs are transforming precision medicine by offering targeted treatments for chronic and genetic diseases, traditional manufacturing methods for peptides face significant inefficiencies. Such limitations restrict production scalability and patient access, highlighting the urgent need for innovative solutions.​

PeptiSystems addresses these challenges through its proprietary solid-phase flowthrough technology. By reducing peptide production times by up to 90% and cutting raw material usage by 70%, this technology enables pharmaceutical companies to scale production efficiently and sustainably, meeting both industry needs and environmental demands.

“This funding is a pivotal milestone for PeptiSystems,” says Karin Granath, CEO of PeptiSystems. “It enables us to expand our production capacity, scale operations globally, and continue developing technologies that not only address growing demand but also align with the industry’s drive for sustainability and innovation. We are grateful for the strong support from our investors and excited to embark on this next phase of growth.”

“Peptide and oligonucleotide drugs are undergoing a transformation, with an increasing number of candidates targeting common diseases like type 2 diabetes and cancer. This development drives demand for more efficient manufacturing solutions. For peptides, PeptiSystems’ technology is a breakthrough that addresses bottlenecks in the process and enables faster drug development,” says Andreas Lindblom, Managing Partner at Sciety. “We are proud to support their continued growth and look forward to seeing their solutions set new standards for efficiency and sustainability in pharmaceutical manufacturing.”

​Since launching its products in 2021, PeptiSystems has seen strong market traction. In 2023, the company generated SEK 33 million in revenue, a significant increase from SEK 9.8 million in 2022. PeptiSystems’ customer base spans the US, Europe, and Asia, including clients like Corden Pharma, a leading CDMO with over 450 global customers. With this investment, PeptiSystems is well-positioned to further strengthen its presence in key markets and continue addressing the growing global demand for peptide and oligonucleotide drugs.

For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: [email protected]

About PeptiSystems AB
PeptiSystems is a biotech company offering a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Leveraging proprietary flow-through column technology, PeptiSystems’ instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for efficient, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.